X4 Pharmaceuticals, Inc. (XFOR)

NASDAQ: XFOR · Real-Time Price · USD

4.040

+0.010 (0.25%)

At close: Aug 21, 2026, 4:00 PM EDT

4.127

+0.087 (2.15%)

After-hours: Aug 21, 2026, 7:30 PM EDT

X4 Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	15.85	35.11	2.56	-	-	-
Revenue Growth	-51.65%	1273.21%	-14.77%	-	-	-
Cost of Revenue	2.93	5.76	0.8	-	-	-
Gross Profit	12.92	29.36	1.76	-	-	-
Selling, General & Admin	29.35	38.52	61.52	35.51	27.02	24.7
Research & Development	64.24	70.72	81.64	72.02	61.06	50.65
Operating Expenses	93.59	109.24	143.16	107.52	88.08	75.35
Operating Income	-80.67	-79.88	-141.4	-107.52	-88.08	-75.35
Interest Expense	-8.74	-8.88	-8.77	-5.78	-3.99	-3.64
Interest & Investment Income	6.97	4.58	5.77	4.58	0.22	0.01
Other Non Operating Income (Expenses)	-0.49	12.03	2.26	7.63	-2.5	0.06
EBT Excluding Unusual Items	-82.93	-72.16	-142.14	-101.09	-94.35	-78.92
Merger & Restructuring Charges	-7.24	-7	-	-	-	-
Impairment of Goodwill	-	-	-	-	-	-9.76
Gain (Loss) on Sale of Assets	-	-	105	-	0.51	-
Pretax Income	-90.17	-79.16	-37.14	-101.09	-93.84	-88.68
Income Tax Expense	-0.03	0.04	0.31	0.08	0.03	0.02
Net Income	-90.14	-79.2	-37.45	-101.17	-93.87	-88.7
Preferred Dividends & Other Adjustments	-	-	-	-	2.55	13.94
Net Income to Common	-90.14	-79.2	-37.45	-101.17	-96.41	-102.64
Net Income Growth	-	-	-	-	-	-
Shares Outstanding (Basic)	102	42	7	6	2	1
Shares Outstanding (Diluted)	102	42	7	6	2	1
Shares Change	1374.07%	531.04%	13.08%	179.91%	146.71%	28.25%
EPS (Basic)	-0.88	-1.87	-5.59	-17.07	-45.53	-119.59
EPS (Diluted)	-0.89	-1.87	-5.59	-17.07	-45.53	-119.59
EPS Growth	-	-	-	-	-	-

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Free Cash Flow	-83.74	-85.62	-131.23	-96.57	-77.21	-71.52
Free Cash Flow Per Share	-0.82	-2.02	-19.58	-16.29	-36.46	-83.33
Gross Margin	81.51%	83.60%	68.83%	-	-	-
Operating Margin	-509.06%	-227.50%	-5529.96%	-	-	-
Profit Margin	-568.80%	-225.56%	-1464.61%	-	-	-
Free Cash Flow Margin	-528.40%	-243.84%	-5132.07%	-	-	-
EBITDA	-79	-78.61	-140.61	-107.1	-87.57	-74.85
EBITDA Margin	-	-223.87%	-	-	-	-
D&A For EBITDA	1.67	1.28	0.8	0.42	0.51	0.5
EBIT	-80.67	-79.88	-141.4	-107.52	-88.08	-75.35
EBIT Margin	-	-227.50%	-	-	-	-
Revenue as Reported	15.85	35.11	2.56	-	-	-

SEC Filings: 10-K · 10-Q